keyword
https://read.qxmd.com/read/38646109/vitiligo-in-a-patient-receiving-adalimumab-for-idiopathic-uveitis
#1
JOURNAL ARTICLE
Mehmet Fatih Kağan Değirmenci, Fatime Nilüfer Yalçındağ
In recent years, adalimumab has been increasingly used in the chronic treatment of non-infectious uveitis. This case report aimed to describe a drug-induced adverse event in a 34-year-old man who presented with blurred vision and floaters in the right eye and was being treated for intermediate uveitis. The patient had started topical treatment with a diagnosis of uveitis at another center. Best corrected visual acuity at presentation was 0.8 (decimal) in the right eye and 1.0 in the left eye. On examination, the anterior chamber in the right eye was clear, with anterior vitreous cells and mild haze, and snow banking and vitreous opacities in the inferior periphery...
April 19, 2024: Turkish Journal of Ophthalmology
https://read.qxmd.com/read/38593259/effects-of-topical-0-05-cyclosporine-a-on-dry-eye-symptoms-and-parameters-following-small-incision-lenticule-extraction
#2
JOURNAL ARTICLE
Xiaofeng Zhu, Shanshan Li, Min Wang, Wenbo Yao, Xinhui Huang, Liquan Zhao
PURPOSE: To evaluate the effects of topical 0.05% cyclosporine A on Ocular Surface Disease Index (OSDI) score and ocular surface parameters after small incision lenticule extraction (SMILE) for myopia. METHODS: In this study, 151 patients who underwent SMILE were randomized into the control group (71 eyes) and the 0.05% cyclosporine A group (80 eyes). Both groups received standard treatment during the 1 month after SMILE. Over the next 3 months, The control group continued standard therapy (0...
April 2024: Journal of Refractive Surgery
https://read.qxmd.com/read/38589911/mucoadhesive-antioxidant-and-lubricant-catechol-functionalized-poly-phosphobetaine-as-biomaterial-nanotherapeutics-for-treating-ocular-dryness
#3
JOURNAL ARTICLE
Hoang Linh Bui, Yun-Han Su, Chia-Jung Yang, Chun-Jen Huang, Jui-Yang Lai
Dry eye disease (DED) is associated with ocular hyperosmolarity and inflammation. The marketed topical eye drops for DED treatment often lack bioavailability and precorneal residence time. In this study, we investigated catechol-functionalized polyzwitterion p(MPC-co-DMA), composed of 2-methacryloyloxyethyl phosphorylcholine (MPC) and dopamine methacrylamide (DMA) monomers, as potential topical nanotherapeutics for DED. The copolymers were synthesized via random free-radical copolymerization, producing different proportions of catecholic functionalization...
April 8, 2024: Journal of Nanobiotechnology
https://read.qxmd.com/read/38542454/a-breakthrough-in-the-treatment-of-necrobiosis-lipoidica-update-on-treatment-etiopathogenesis-diagnosis-and-clinical-presentation
#4
REVIEW
Maciej Naumowicz, Stefan Modzelewski, Angelika Macko, Bartosz Łuniewski, Anna Baran, Iwona Flisiak
Necrobiosis lipoidica (NL) is a rare granulomatous disease of a not fully understood etiopathogenesis. Classically, NL is associated with insulin-dependent diabetes mellitus. The disease often fails to respond to conventional treatments and adversely affects patients' quality of life. First-line medications are usually topical corticosteroids, but patients respond to them with varying degrees of success. Other options include tacrolimus, phototherapy, cyclosporine, fumaric acid esters, and biologics (adalimumab, etanercept, and infliximab)...
March 20, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38541686/vernal-keratoconjunctivitis-immunopathological-insights-and-therapeutic-applications-of-immunomodulators
#5
REVIEW
Navpreet K Hehar, DeGaulle I Chigbu
Vernal keratoconjunctivitis (VKC) is a complex and multifactorial disease process that employs Th2 cell-mediated immunologic processes, which involves the overexpression of interleukin 4 (IL-4), IL-5, IL-9, IL-13, and IL-31, and the activation of mast cells that release IL-5 and CCL-11, recruiting eosinophils to the site of inflammation. The disease primarily affects young males and is more common in regions with warm climates. VKC is characterized by persistent and recurrent conjunctival inflammation that can adversely affect the patient's quality of life, and, when inadequately treated, may lead to a host of ocular complications, such as corneal shield ulcers and scarring...
March 9, 2024: Life
https://read.qxmd.com/read/38529623/clinical-pharmacokinetics-and-pharmacodynamics-of-oral-systemic-nonbiologic-therapies-for-psoriasis-patients
#6
REVIEW
Justin M Eichinger, Divya M Shan, Jonathan D Greenzaid, Lisa Anakwenze, Steven R Feldman
INTRODUCTION: Psoriasis is a chronic inflammatory immune condition. Treatments for psoriasis vary with disease severity, ranging from topicals to systemic biologic agents. The pharmacokinetic (PK) and pharmacodynamic (PD) properties of these therapies establish drug efficacy, toxicity, and optimal dosing to ensure therapeutic drug levels are sustained and adverse effects are minimized. AREAS COVERED: A literature search was performed on PubMed, Google Scholar, and Ovid MEDLINE for PK and PD, efficacy, and safety data regarding oral systemic nonbiologic therapies utilized for moderate-to-severe plaque psoriasis...
March 26, 2024: Expert Opinion on Drug Metabolism & Toxicology
https://read.qxmd.com/read/38522861/successful-treatment-of-generalized-pustular-psoriasis-with-guselkumab
#7
JOURNAL ARTICLE
Martina Part
The purpose of the article: Generalized pustular psoriasis (GPP) is a rare auto-inflammatory disease. Patients with GPP may develop life-threatening complications, including sepsis, acute renal failure, neutrophilic cholangitis, high-output congestive heart failure, acute respiratory distress syndrome and death. The therapy of GPP is very limited and the course of the disease is unpredictable. Materials and methods: We report a 60-year-old woman presenting with widespread and confluent erythematous-desquamative plaques with numerous small pustules covering almost 70% of the body surface area...
December 2024: Journal of Dermatological Treatment
https://read.qxmd.com/read/38522059/applications-of-topical-immunomodulators-enhance-clinical-signs-of-vernal-keratoconjunctivitis-vkc-and-atopic-keratoconjunctivitis-akc-a-meta-analysis
#8
REVIEW
Nir Erdinest, Dror Ben Ephraim Noyman, Naomi London, Itay Lavy, Nadav Levinger, David Landau, Abraham Solomon, Yair Morad, Shehzad A Naroo
PURPOSE: This meta-analysis aimed to review the safety and efficacy of topical cyclosporine A (CsA) and topical tacrolimus in allergic eye disease. METHODS: A systematic search identified thirteen studies and a total of 445 patients for inclusion, making this the largest meta-analysis published on the subject. The current review was performed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). RESULTS: Thirteen randomized control trials were included in the meta-analysis...
March 24, 2024: International Ophthalmology
https://read.qxmd.com/read/38472726/cyclosporin-a-loaded-dissolving-microneedles-for-dermatitis-therapy-development-characterisation-and-efficacy-in-a-delayed-type-hypersensitivity-in-vivo-model
#9
JOURNAL ARTICLE
Miquel Martínez-Navarrete, Antonio José Guillot, Maria C Lobita, María Carmen Recio, Rosa Giner, Juan Aparicio-Blanco, María Carmen Montesinos, Hélder A Santos, Ana Melero
Several drugs can be used for treating inflammatory skin pathologies like dermatitis and psoriasis. However, for the management of chronic and long-term cases, topical administration is preferred over oral delivery since it prevents certain issues due to systemic side effects from occurring. Cyclosporin A (CsA) has been used for this purpose; however, its high molecular weight (1202 Da) restricts the diffusion through the skin structure. Here, we developed a nano-in-micro device combining lipid vesicles (LVs) and dissolving microneedle array patches (DMAPs) for targeted skin delivery...
March 12, 2024: Drug Delivery and Translational Research
https://read.qxmd.com/read/38446281/short-term-efficacy-of-ophthalmic-cyclosporine-a-0-1-cationic-emulsion-in-dry-eye-patients-assessed-under-controlled-environment
#10
JOURNAL ARTICLE
Laura Valencia-Nieto, José Pinto-Fraga, Marta Blanco-Vázquez, Itziar Fernández, Alberto López-Miguel, Carmen García-Vázquez, María J González-García, Amalia Enríquez-de-Salamanca, Margarita Calonge
INTRODUCTION: To evaluate the short-term efficacy of cyclosporine A (CsA)-0.1% cationic emulsion (CE) in patients with dry eye disease (DED) and mitigation of the inflammatory flares triggered by desiccating stress environments. METHODS: A single-center non-randomized clinical trial was performed at a tertiary care setting. Twenty patients with DED treated with CsA 0.1% CE were exposed to a normal controlled environment (NCE) (23 °C, 50% relative humidity) and an adverse controlled environment (ACE) (23 °C, 10% relative humidity, 0...
March 6, 2024: Ophthalmology and Therapy
https://read.qxmd.com/read/38436902/a-patient-centered-approach-to-vernal-keratoconjunctivitis-vkc-a-podcast
#11
JOURNAL ARTICLE
Ann Cathrine Larsen, Marie Louise Roed Rasmussen
Vernal keratoconjunctivitis (VKC) is a rare yet severe form of allergic conjunctivitis predominantly affecting children, mainly boys, with a global prevalence and a higher incidence in certain geographical regions. The disease is characterized by seasonal exacerbations. VKC presents with ocular surface inflammation leading to various distressing symptoms such as itching, redness, mucous discharge, and pain. The disease primarily manifests bilaterally, though it may initially appear unilaterally. If left untreated, VKC can result in corneal complications, including shield ulcers and vision impairment, affecting daily activities and psychosocial well-being, especially in children...
March 4, 2024: Ophthalmology and Therapy
https://read.qxmd.com/read/38423448/chronic-vulvar-aphthous-ulcer-in-crohn-s-disease
#12
JOURNAL ARTICLE
Shivani Jain, Jennifer Foster, Melissa M Mauksar
No abstract text is available yet for this article.
February 27, 2024: American Journal of Obstetrics and Gynecology
https://read.qxmd.com/read/38408759/phosphatidylserine-accelerates-wound-healing-and-reduces-necrosis-in-the-rats-growth-factor-activation
#13
JOURNAL ARTICLE
Partow Mirzaee Saffari, Pooria Asili, Sadaf Eshraghi, Ahad Muhammadnejad, Ahmad Reza Dehpour, Ramin Goudarzi, Alireza Partoazar
To examine the effect of topical phosphatidylserine (PS) on wound healing factors and tissue necrosis in in vivo models. Topical PS was applied to evaluate aspects of the wound healing process and growth factors production of vascular endothelial growth factors (VEGF) as well a necrosis reduction in the skin flap of rat models. Moreover, phenytoin (PHT) and cyclosporine A (CsA) were used topically as positive control treatments in wound and necrosis models, respectively. Immunohistochemistry (IHC) VEGF, transforming growth factor-β (TGF-β), fibroblast growth factor (FGF) and histopathology were analysed on the wounds of rats...
April 2024: Clinical and Experimental Pharmacology & Physiology
https://read.qxmd.com/read/38402151/anti-psoriatic-characteristics-of-rocen-topical-arthrocen-in-comparison-with-cyclosporine-a-in-a-murine-model
#14
JOURNAL ARTICLE
Ramin Goudarzi, Min-Ho Kim, Alireza Partoazar
Topical ROCEN (Roc), liposomal arthrocen hydrogel, is a robust anti-inflammatory formulation which has been developed for skin diseases such as eczema. Therefore, we aimed to evaluate the efficacy of Roc 2% on the healing of imiquimod (Imiq)-induced psoriasis in a mouse model. Psoriasis was induced by applying Imiq topically to the mice's back skin once daily for five consecutive days. Moreover, a group of animal experiments was treated with Cyclosporine A (CsA), as a standard drug, for comparison with Roc treated group...
February 24, 2024: BMC complementary medicine and therapies
https://read.qxmd.com/read/38356795/recent-progress-of-nanomedicine-in-managing-dry-eye-disease
#15
REVIEW
Zeen Lv, Su Li, Guixiang Zeng, Ke Yao, Haijie Han
BACKGROUND: Dry eye disease (DED) is a commonly reported ocular complaint that has garnered significant attention in recent research. The global occurrence of DED ranges from 5% to 50%, impacting a substantial proportion of individuals worldwide with increasing frequency. Although topical administration remains the mainstream drug delivery method for ocular diseases, it suffers from drawbacks such as low bioavailability, rapid drug metabolism, and frequent administration requirements...
2024: Adv Ophthalmol Pract Res
https://read.qxmd.com/read/38344440/revolutionizing-psoriasis-topical-treatment-enhanced-efficacy-through-ceramide-phospholipid-composite-cerosomes-co-delivery-of-cyclosporine-and-dithranol-in-vitro-ex-vivo-and-in-vivo-studies
#16
JOURNAL ARTICLE
Sammar Fathy Elhabal, Nashwa Abdelaal, Saeed A S Al-Zuhairy, Mohamed Fathi Mohamed Elrefai, Mohamed Mansour Khalifa, Mohammad Ahmad Khasawneh, Ahmed Mohsen Elsaid Hamdan, Passant M Mohie, Rania A Gad, Soad L Kabil, Mohamed Kandeel El-Ashery, Bhaskara R Jasti, Nahla A Elzohairy, Nehal Elfar, Tayseer Elnawawy, Fatma E Hassan, Mohamed Ahmed El-Nabarawi
PURPOSE: Improving the treatment of psoriasis is a serious challenge today. Psoriasis is an immune-mediated skin condition affecting 125 million people worldwide. It is commonly treated with cyclosporine-A (CsA) and dithranol (DTH). CsA suppresses the activation of T-cells, immune cells involved in forming psoriatic lesions. Meanwhile, DTH is a potent anti-inflammatory and anti-proliferative drug that effectively reduces the severity of psoriasis symptoms such as redness, scaling, and skin thickness...
2024: International Journal of Nanomedicine
https://read.qxmd.com/read/38334413/efficacy-of-a-novel-water-free-topical-cyclosporine-0-1-solution-for-optimizing-the-ocular-surface-in-patients-with-dry-eye-and-cataract
#17
JOURNAL ARTICLE
Esen K Akpek, John D Sheppard, Adam Hamm, Simone Angstmann-Mehr, Sonja Krösser
This is a pooled analysis from two phase III clinical trials investigating a water-free topical cyclosporine 0.1% for the treatment of moderate to severe dry eye. The analyses included 1162 patients: 35% with cataract, 20% with pseudophakia and 45% without cataract. Demographics or baseline characteristics were comparable across groups except for age and vision. The cyclosporine treated patients achieved large mean improvements from baseline by day 15: -3.7 in patients without cataract, -3.2 in patients with cataract and -3...
February 9, 2024: Journal of Cataract and Refractive Surgery
https://read.qxmd.com/read/38323796/conjunctival-and-nasal-microflora-in-patients-on-topical-cyclosporine-for-dry-eye
#18
JOURNAL ARTICLE
Emine S Elibol, Zafer Habip, Ahmet Elbay, Ahmet Adnan Cırık, Halit Oğuz
Introduction: Dry eye is a common ocular condition causing discomfort and visual disturbances. Anti-inflammatory agents like Cyclosporine A (CsA) are often used in its treatment. However, the impact of CsA on ocular flora remains understudied. This research aimed to evaluate changes in conjunctival and nasal microflora in patients receiving topical cyclosporine for dry eye. Methods: In this cross-sectional study, conjunctival and nasal samples were collected from two groups of dry eye patients. Group 1 consisted of 38 patients using CsA eye drops, while Group 2 included 34 patients using preservative-free artificial tear drops...
2024: International Journal of Immunopathology and Pharmacology
https://read.qxmd.com/read/38310173/aplastic-anemia-history-and-recent-developments-in-diagnosis-and-treatment
#19
EDITORIAL
Yasushi Onishi
Acquired aplastic anemia is an immune-mediated disease that targets hematopoietic stem cells, which is diagnosed by findings of peripheral blood pancytopenia and hypocellular bone marrow. Although the diagnostic definition is simple, differential diagnosis from other overlapping hematopoietic disorders such as hypoplastic myelodysplastic syndrome and inherited bone marrow failure syndrome is not easy. Immune suppressive therapy and allogeneic hematopoietic stem cell transplantation are important treatment approaches for aplastic anemia, and both have advanced in recent years...
February 4, 2024: International Journal of Hematology
https://read.qxmd.com/read/38302687/rapidly-dissolving-trans-scleral-microneedles-for-intraocular-delivery-of-cyclosporine-a
#20
JOURNAL ARTICLE
Hamad Alrbyawi, Manjusha Annaji, Oladiran Fasina, Srinath Palakurthi, Sai H S Boddu, Nageeb Hassan, Amit K Tiwari, Amol Suryawanshi, R Jayachandra Babu
Cyclosporine A (CsA) is a cyclic peptide immunosuppressant drug that is beneficial in the treatment of various ocular diseases. However, its ocular bioavailability in the posterior eye is limited due to its poor aqueous solubility. Conventional CsA formulations such as a solution or emulsion permeate poorly across the eye due to various static and dynamic barriers of the eye. Dissolvable microneedle (MN)-based patches can be used to overcome barrier properties and, thus, enhance the ocular bioavailability of CsA in the posterior eye...
February 1, 2024: AAPS PharmSciTech
keyword
keyword
36427
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.